Ibrutinib: A narrative drug review
Ibrutinib is an oral, irreversible covalent inhibitor of the Bruton tyrosine kinase, that plays a major role in B-cell differentiation, proliferation, migration, survival, and apoptosis. It has been found to be active against a number of B-cell malignancies. Ibrutinib has shifted the treatment strat...
Main Authors: | Pritesh Naresh Munot, Sumeet Mirgh, Nikita Mehra, Bhausaheb P Bagal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Cancer Research, Statistics, and Treatment |
Subjects: | |
Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2020;volume=3;issue=4;spage=767;epage=784;aulast=Munot |
Similar Items
-
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
by: C. I. Edvard Smith, et al.
Published: (2021-06-01) -
Waldenström macroglobulinemia: biology, genetics, and therapy
by: Paludo J, et al.
Published: (2016-07-01) -
Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
by: Anantha Sriharsha Madgula, MBBS, et al.
Published: (2020-09-01) -
Splenic re-irradiation for waldenstrőm’s macroglobulinemia
by: Wei Zhou, et al.
Published: (2012-04-01) -
Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review
by: Jessica D. Rich, et al.
Published: (2019-10-01)